VistaGen Therapeutics Inc... (VTGN)
NASDAQ: VTGN
· Real-Time Price · USD
3.65
0.05 (1.39%)
At close: Oct 03, 2025, 3:59 PM
3.53
-3.29%
After-hours: Oct 03, 2025, 07:45 PM EDT
1.39% (1D)
| Bid | 3.49 |
| Market Cap | 111.98M |
| Revenue (ttm) | 646K |
| Net Income (ttm) | -55.78M |
| EPS (ttm) | -1.79 |
| PE Ratio (ttm) | -2.04 |
| Forward PE | -2.22 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 3.75 |
| Volume | 501,642 |
| Avg. Volume (20D) | 538,709 |
| Open | 3.61 |
| Previous Close | 3.60 |
| Day's Range | 3.48 - 3.71 |
| 52-Week Range | 1.90 - 3.88 |
| Beta | 0.54 |
| Ex-Dividend Date | n/a |
About VTGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VTGN
Website n/a
VistaGen Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptVistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief...
2 months ago · fool.com
Vistagen (VTGN) Q1 R&D Expense Jumps 54%Vistagen (VTGN) Q1 R&D Expense Jumps 54%
2 months ago · businesswire.com
Vistagen to Present at the BTIG Virtual Biotechnology ConferenceSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
2 months ago · businesswire.com
Vistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...